Amorphous nanodrugs prepared by complexation with polysaccharides: Carrageenan versus dextran sulfate

Carbohydrate Polymers

Volumn 117, Issue , 2015, Pages 549-558

  Cheow, Wean Sin ^a   Kiew, Tie Yi ^a   Hadinoto, Kunn ^a  

^a Nanyang Technological University   (Singapore)

Author keywords

Colloidal polysaccharides; Drug polysaccharide complex; Nanomedicine; Polysaccharide nanoparticles; Supersaturated drug delivery system

Indexed keywords

CARRAGEENANS; DEXTRAN SULFATES; DRUG DELIVERY SYSTEM; DRUG-POLYSACCHARIDE COMPLEX; NANODRUGS;

MEDICAL NANOTECHNOLOGY;

ANTIINFECTIVE AGENT; CARRAGEENAN; CIPROFLOXACIN; DEXTRAN SULFATE; NANOCAPSULE; POLYSACCHARIDE;

CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ESCHERICHIA COLI; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; PARTICLE SIZE; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY; TUMOR CELL LINE;

ANTI-BACTERIAL AGENTS; CARRAGEENAN; CELL LINE, TUMOR; CIPROFLOXACIN; DEXTRAN SULFATE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; NANOCAPSULES; PARTICLE SIZE; POLYSACCHARIDES; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PROPERTIES;

EID: 84908431967     PISSN: 01448617     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carbpol.2014.10.015     Document Type: Article

References (25)

1. Alonzo, D., Zhang, G., Zhou, D., Gao, Y., & Taylor, L. (2010). Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharmaceutical Research, 27(4), 608-618.
2. Ando, H. Y., & Radebaugh, G. W. (2005). Property-based drug design and preformulation. In D. B. Troy (Ed.), Remington: The science and practice of pharmacy. Philadelphia, PA: Lippincott Williams & Wilkins.
3. Augustijns, P., & Brewster, M. E. (2012). Supersaturating drug delivery systems: Fast is not necessarily good enough. Journal of Pharmaceutical Sciences, 101(1), 7-9.
4. Caram-Lelham, N., Hed, F., & Sundelof, L. O. (1997). Adsorption of charged amphiphiles to oppositely charged polysaccharides-A study of the in.uence of polysaccharide structure and hydrophobicity of the amphiphile molecule. Biopolymers, 41(7), 765-772.
5. Cheow, W. S., & Hadinoto, K. (2012). Self-assembled amorphous drugpolyelectrolyte nanoparticle complex with enhanced dissolution rate and saturation solubility. Journal of Colloid and Interface Science, 367, 518-526.
6. Cheow, W. S., Kiew, T. Y., Yang, Y., & Hadinoto, K. (2014). Amorphization strategy affects the stability and supersaturation profile of amorphous drug nanoparticles. Molecular Pharmaceutics, 11(5), 1611-1620.
7. Delair, T. (2011). Colloidal polyelectrolyte complexes of chitosan and dextran sulfate towards versatile nanocarriers of bioactive molecules. European Journal of Pharmaceutics and Biopharmaceutics, 78(1), 10-18.
8. Dhumal, R. S., Biradar, S. V., Yamamura, S., Paradkar, A. R., & York, P. (2008). Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability. European Journal of Pharmaceutics and Biopharmaceutics, 70(1), 109-115.
9. Hugerth, A., & Sundelof, L. O. (2001). The effect of polyelectrolyte counterion speci.city, charge density, and conformation on polyelectrolyte-amphiphile interaction: The carrageenan/furcellaran amitriptyline system. Biopolymers, 58(2), 186-194.
10. Kara, S., Tamerler, C., & Pekcan, O. (2003). Cation effects on swelling of kcarrageenan: A photon transmission study. Biopolymers, 70(2), 240-251.
11. Li, L., Ni, R., Shao, Y., & Mao, S. R. (2014). Carrageenan and its applications in drug delivery. Carbohydrate Polymers, 103, 1-11.
12. Lindfors, L., Skantze, P., Skantze, U., Rasmusson, M., Zackrisson, A., & Olsson, U. (2006). Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir, 22(3), 906-910.
13. Matteucci, M. E., Brettmann, B. K., Rogers, T. L., Elder, E. J., Williams, R. O., & Johnston, K. P. (2007). Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. Molecular Pharmaceutics, 4(5), 782-793.
14. Mou, D. S., Chen, H. B., Wan, J. L., Xu, H. B., & Yang, X. L. (2011). Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. International Journal of Pharmaceutics, 413(1-2), 237-244.
15. Persson, B., Hugerth, A., Caram-Lelham, N., & Sundelof, L. O. (2000). Dextran sulfateamphiphile interaction; effect of polyelectrolyte charge density and amphiphile hydrophobicity. Langmuir, 16(2), 313-317.
16. Ramasamy, T., Tran, T. H., Cho, H. J., Kim, J. H., Kim, Y. I., Jeon, J. Y., et al. (2014). Chitosan-based polyelectrolyte complexes as potential nanoparticulate carriers: Physicochemical and biological characterization. Pharmaceutical Research, 31(5), 1302-1314.
17. Schatz, C., Domard, A., Viton, C., Pichot, C., & Delair, T. (2004). Versatile and ef.cient formation of colloids of biopolymer-based polyelectrolyte complexes. Biomacromolecules, 5(5), 1882-1892.
18. Siepmann, J., Kranz, H., Bodmeier, R., & Peppas, N. A. (1999). HPMC-matrices for controlled drug delivery: A new model combining diffusion, swelling, and dissolution mechanisms and predicting the release kinetics. Pharmaceutical Research, 16(11), 1748-1756.
19. Slootmaekers, D., Dejonghe, C., Reynaers, H., Varkevisser, F. A., & Vantreslong, C. J. B. (1988). Static light-scattering from kappa-carrageenan solutions. International Journal of Biological Macromolecules, 10(3), 160-168.
20. Sun, D. J. D., & Lee, P. I. (2013). Evolution of supersaturation of amorphous pharmaceuticals: The effect of rate of supersaturation generation. Molecular Pharmaceutics, 10(11), 4330-4346.
21. Tajarobi, F., Larsson, A., Matic, H., & Abrahmsen-Alami, S. (2011). The in.uence of crystallization inhibition of HPMC and HPMCAS on model substance dissolution and release in swellable matrix tablets. European Journal of Pharmaceutics and Biopharmaceutics, 78(1), 125-133.
22. Vandeloosdrecht, A. A., Beelen, R. H. J., Ossenkoppele, G. J., Broekhoven, M. G., & Langenhuijsen, M. (1994). A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic-cells from cell-lines and patients with acute myeloid-leukemia. Journal of Immunological Methods, 174(1-2), 311-320.
23. Wang, Q., Rademacher, B., Sedlmeyer, F., & Kulozik, U. (2005). Gelation behaviour of aqueous solutions of different types of carrageenan investigated by low-intensity-ultrasound measurements and comparison to rheological measurements. Innovative Food Science & Emerging Technologies, 6(4), 465-472.
24. Watase, M., & Nishinari, K. (1986). Rheology, DSC, and volume or weight change induced by immersion in solvents for agarose and kappa-carrageenan gels. Polymer Journal, 18(12), 1017-1025.
25. Zheng, J. (2009). Formulation and analytical development for low-dose oral drug products. New Jersey: John Wiley and Sons.